Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced its results ... fiscal 2014 year-end financial statements and MD&A have been filed on SEDAR ... , 2014 , 2013 Revenue 3,968 , ... 1,326 , 1,703 , 2,231 , ... 3,377 , 4,562 Ebitda* 92 , 418 ...
(Date:4/29/2015)... RUTHERFORD, N.J. , April 29, 2015 Cambrex ... financial results will be released on Friday, May 1, 2015 ... The Company will host a conference call ... Call When: , Friday, May ... , 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  ...
(Date:4/29/2015)... CA (PRWEB) April 29, 2015 The ... to announce that its regenerative stem cell therapy has ... in 2002, seeking to discover a successful treatment for ... , In 2003 VetStem signed a worldwide exclusive license ... application, and the first horse was treated in January ...
(Date:4/29/2015)... 29, 2015 /CNW/ - Northern Biologics Inc., a privately ... announced an exclusive, strategic collaboration with Celgene Corporation. ... a US$30 million upfront cash payment. It will ... therapeutic antibodies, and will have the right to ... of its portfolio. Under the ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... of Wisconsin-Madison spinout that has sped to the finals in ... stop to the annual flu vaccine hoopla, among other things. ... are developing two drugs based on antiviral peptides discovered in ... while the other targets some sexually transmitted viruses such as ...
... recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace ... up in the Merck Vioxx dilemma months ago and its stock ... $25 per share in February. It has recently moved up to ... about 30 percent in the last 12 months. , ,Though Pfizer ...
... Sensient Technologies Corp. (NYSE:SXT) reported $12.8 million ... quarter ended March 31. Diluted earnings per share were 27 ... flavors and fragrances. , ,Revenue was down $3 million since ... a reduction of $19.2 million. , ,Results for the first ...
Cached Biology Technology:UW-Madison spinoff Pedrus finds more to business planning than good science 2UW-Madison spinoff Pedrus finds more to business planning than good science 3Why are new drugs failing? 2Why are new drugs failing? 3Why are new drugs failing? 4Why are new drugs failing? 5Why are new drugs failing? 6
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... The University of Chicago Celiac Disease Center is hosting ... 22-25, 2013 in Chicago. The symposium is the largest ... The meeting, which follows the 2011 conference in Oslo, ... United States since 2006. The Chicago meeting seeks ...
... Paris, France, dedicated to improving human health through international ... grant award to a new global research network of ... Research Center at Icahn School of Medicine at Mount ... as part of the Fondation Leducq,s Transatlantic Networks of ...
... in a wide range of problems from arthritis to cardiovascular ... temper this problem. A new research report appearing in the ... , helps explain why DHA is important in reducing inflammation, ... will help bring people back to optimal health. Specifically, researchers ...
Cached Biology News:UChicago Celiac Disease Center to host international symposium 2Fondation Leducq awards $6 million grant for global research network for cardiac regeneration 2Fondation Leducq awards $6 million grant for global research network for cardiac regeneration 3Harvard and USC scientists show how DHA resolves inflammation 2
... Electron RapidStak provides valuable walk-away time and ... buffer nest technology for parallel processing of ... fast, reliable automation for any laboratory in ... The RapidStak can be set-up within minutes ...
... polyclonal to MLF1 Interacting Protein/PBIP1 (phospho ... tested applications). Antigen: ... amino acids 73-83 of Human MLF1 ... Gene ID: 359815 ...
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
Biology Products: